Keywords
ImmunotherapyLung cancerDiseaseMedicineCancerPopulationTyrosine kinaseOncologyOverall survivalIntensive care medicineInternal medicineBiologyCancer researchEnvironmental health
Affiliated Institutions
Related Publications
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a plat...
Diagnosing and Managing Advanced Chronic Myeloid Leukemia
Clinical staging of chronic myeloid leukemia (CML) distinguishes between chronic phase (CP-CML), accelerated phase (AP-CML), and blastic phase (BP-CML), reflecting its natural h...
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in si...
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival...
Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer
A companion diagnostic assay was codeveloped by Dako for pembrolizumab non–small-cell lung cancer clinical trials to detect PD-L1 expression by immunohistochemistry (IHC). This ...
Publication Info
- Year
- 2018
- Type
- review
- Volume
- 553
- Issue
- 7689
- Pages
- 446-454
- Citations
- 4607
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
4607
OpenAlex
Cite This
Roy S. Herbst,
Daniel Morgensztern,
Chris Boshoff
(2018).
The biology and management of non-small cell lung cancer.
Nature
, 553
(7689)
, 446-454.
https://doi.org/10.1038/nature25183
Identifiers
- DOI
- 10.1038/nature25183